Literature DB >> 29468722

Podoplanin-positive myofibroblasts: a pathological hallmark of pleuroparenchymal fibroelastosis.

Yasunori Enomoto1,2, Sayomi Matsushima1,2, Shiori Meguro1, Hideya Kawasaki1, Isao Kosugi1, Tomoyuki Fujisawa2, Noriyuki Enomoto2, Naoki Inui2, Yutaro Nakamura2, Takafumi Suda2, Toshihide Iwashita1.   

Abstract

Pathological differential diagnoses of pleuroparenchymal fibroelastosis (PPFE) include usual interstitial pneumonia (UIP) and pulmonary apical cap (PAC); however, there are no specific immunostaining makers to distinguish between these diseases. We performed immunohistochemistry using several pleural mesothelial cell-related markers, including cytokeratin-5/6, CAM5.2, WT-1, calretinin, desmin and podoplanin, for PPFE (n = 4), UIP (n = 10) and PAC (n = 3) lung sections. Among the examined markers, in PPFE and PAC lungs podoplanin commonly showed positivity for spindle cells both in thickened pleura and subpleural fibroelastosis lesions; these cells were also stained with α-smooth muscle actin, a marker of myofibroblasts. However, even in elastic fibre-rich cases, UIP lungs did not show such podoplanin-positive myofibroblasts in pleura/subpleura and fibroblastic foci. These findings were also verified using immunofluorescence. By contrast, immunohistochemically as well as morphologically, the difference between PPFE and PAC was not apparent. The presence of podoplanin-positive myofibroblasts could be a pathological hallmark of PPFE, suggesting a pathogenic process distinct from UIP but common to PAC.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  myofibroblast; pleuroparenchymal fibroelastosis; podoplanin; pulmonary apical cap; usual interstitial pneumonia

Mesh:

Year:  2018        PMID: 29468722     DOI: 10.1111/his.13494

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Kazuki Nabeshima; Kentato Watanabe
Journal:  Histol Histopathol       Date:  2020-12-14       Impact factor: 2.303

2.  Metformin reduces pleural fibroelastosis by inhibition of extracellular matrix production induced by CD90-positive myofibroblasts.

Authors:  Yoichiro Aoshima; Yasunori Enomoto; Atsuki Fukada; Yuki Kurita; Sayomi Matsushima; Shiori Meguro; Isao Kosugi; Hideya Kawasaki; Hiroaki Katsura; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Takafumi Suda; Toshihide Iwashita
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 3.  Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics.

Authors:  Felix Chua; Sujal R Desai; Andrew G Nicholson; Anand Devaraj; Elisabetta Renzoni; Alexandra Rice; Athol U Wells
Journal:  Ann Am Thorac Soc       Date:  2019-11

4.  Acute Exacerbation of Pleuroparenchymal Fibroelastosis Secondary to Allogenic Hematopoietic Stem Cell Transplantation.

Authors:  Yasushi Murakami; Koji Sakamoto; Yuki Okumura; Atsushi Suzuki; Shinji Mii; Mitsuo Sato; Toyoharu Yokoi; Naozumi Hashimoto; Yoshinori Hasegawa
Journal:  Intern Med       Date:  2020-07-14       Impact factor: 1.271

5.  Cryobiopsies are diagnostic in Pleuroparenchymal and Airway-centered Fibroelastosis.

Authors:  Sissel Kronborg-White; Claudia Ravaglia; Alessandra Dubini; Sara Piciucchi; Sara Tomassetti; Elisabeth Bendstrup; Venerino Poletti
Journal:  Respir Res       Date:  2018-07-13

6.  Paradoxical Formation of a Pleuroparenchymal Fibroelastosis-like Lesion in the Chronic Course of Pulmonary Sarcoidosis.

Authors:  Michiru Sawahata; Takeshi Johkoh; Takeshi Kawanobe; Chiyoko Kono; Takuji Suzuki; Masashi Bando; Koichi Hagiwara; Noriharu Shijubo; Satoshi Konno; Tetsuo Yamaguchi
Journal:  Intern Med       Date:  2021-08-06       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.